Press release
NYX-783 Market Size and Share Analysis Across 7MM and Competitive Landscape by DelveInsight | Key Players - Aptinyx
The extensive report offers a thorough examination of the market potential and market share of NYX-783 in the therapeutics landscape for Post-traumatic Stress Disorder (PTSD) across the 7MM spanning the years 2019 to 2032. By delving into this analysis, stakeholders gain valuable insights into the evolving landscape of NYX-783, encompassing both clinical and commercial dimensions. Key parameters such as the drug's Mechanism of Action (MOA), Route of Administration (ROA), dosage, and any special designations are meticulously explored, providing a holistic understanding of its profile.
Explore key clinical, commercial, and regulatory milestones associated with NYX-783 by visiting:
https://www.delveinsight.com/report-store/nyx-783-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
NYX-783 Drug Insights
NYX-783 stands as a groundbreaking oral, small molecule designed by Aptinyx to target the N-methyl-D-aspartate receptor (NMDAR) in the context of Post-traumatic Stress Disorder (PTSD). Aptinyx's research into NYX-783 has yielded promising results in preclinical trials, particularly demonstrating significant efficacy in psychiatric models, fear extinction models, and substance abuse models.
Currently, NYX-783 is advancing through Phase 2b clinical trials aimed at treating PTSD. Aptinyx is actively recruiting participants for a Phase 2b trial assessing the safety and effectiveness of a 50 mg dosage of NYX-783 in approximately 300 patients diagnosed with PTSD.
Get a detailed overview of the NYX-783 drug and stay ahead of the competition by leveraging key insights @
https://www.delveinsight.com/report-store/nyx-783-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Key Highlights of the NYX-783 Market Report
• The report includes a projected assessment of NYX-783 sales for Post-traumatic Stress Disorder (PTSD) up to the year 2032.
• The report offers in-depth coverage of advanced-stage emerging therapies for the treatment of Post-traumatic Stress Disorder.
• The report additionally includes both qualitative and quantitative analyses conducted by analysts, along with Key Opinion Leader (KOL) perspectives on NYX-783 for Post-traumatic Stress Disorder.
Why NYX-783 Market Report?
• The projected market data for NYX-783 in the context of Post-traumatic Stress Disorder (PTSD) will play a crucial role in informing decision-making related to the therapeutic portfolio. It will provide valuable insights into the overall landscape of NYX-783, aiding in strategic planning and decision-making processes within the therapeutic domain.
• A comprehensive market forecast for NYX-783 will contribute to a better understanding of how the drug competes with other emerging therapies within the therapeutics landscape. This analysis will provide insights into the drug's positioning, potential market share, and overall impact on the competitive environment in the therapeutic field.
• The report additionally offers future market assessments for the NYX-783 market in the field of Post-traumatic Stress Disorder across the 7 Major Markets. It encompasses advanced qualitative analyses such as SWOT analysis, insights from expert analysts, a comprehensive overview of market competitors, and a brief analysis of other emerging therapies within the realm of Post-traumatic Stress Disorder. This multifaceted approach ensures a comprehensive understanding of the NYX-783 market landscape, combining both quantitative and qualitative perspectives for a well-rounded assessment.
• Conducting a thorough market forecast for NYX-783 will facilitate a detailed analysis of the drug's clinical trial progress. This examination will encompass a comprehensive assessment of the clinical, regulatory, and commercial aspects, providing valuable insights into the advancements of NYX-783.
Visit and Explore How NYX-783 Is Set to Dominate the Post-traumatic Stress Disorder Therapeutic Market:
https://www.delveinsight.com/sample-request/nyx-783-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Contents of the Report
1. Report Introduction
2. NYX-783 Overview in Post-traumatic Stress Disorder
3. Competitive Landscape (Key Assessment of the Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies Analysis)
5. NYX-783 Market Assessment
6. SWOT Analysis
7. Analysts' Views
8. Appendix
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
* The final table of contents may be subject to change based on user demand.
Request the Sample PDF to Learn More About the Key Offerings of the NYX-783 Market Report @
https://www.delveinsight.com/sample-request/nyx-783-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
----------------------------------------------------------------------------------------------------------------------------------
Other Related Reports By DelveInsight
Post-traumatic Stress Disorder (PTSD) Pipeline Insight
DelveInsight's "Post-traumatic Stress Disorder Pipeline Insight" report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Post-traumatic Stress Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by routes of administration, and molecule types. Furthermore, it further highlights the inactive pipeline products in this space. Some of the key companies in the Post-traumatic Stress Disorder Therapeutics market include Aptinyx, Jazz Pharmaceuticals, Bionomics Limited, Boehringer Ingelheim, Otsuka Pharmaceutical Development & Commercialization, Inc., GlaxoSmithKline, AstraZeneca, Remedy, H. Lundbeck A/S, Alto Neuroscience, Yale University, Sage Therapeutics, Pfizer, Tonix Pharmaceuticals, Inc., and Nobilis Therapeutics, and others. Visit & explore how the Post-traumatic Stress Disorder therapeutics pipeline is evolving, at:
https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release NYX-783 Market Size and Share Analysis Across 7MM and Competitive Landscape by DelveInsight | Key Players - Aptinyx here
News-ID: 3391517 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Stress
Leading Element Driving Change in the Stress Toy Market in 2025: Rising Stress A …
What Is the Estimated Market Size and Growth Rate for the Stress Toy Market?
In recent years, there has been a significant expansion in the stress toy market. The market, which was valued at $5.52 billion in 2024, is projected to increase to $5.88 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.6%. Several factors have contributed to growth during this historical period, including a higher incidence of…
Key Driver Reshaping the Stress Tracking Devices Market in 2025: Rising Stress-R …
"What Are the Projections for the Size and Growth Rate of the Stress Tracking Devices Market?
The market size for stress tracking devices has seen significant expansion in the past few years. Projected growth is from $3.14 billion in 2024 to $3.43 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 9.3%. The key factors that have contributed to growth over the historical period include the upsurge in stress-related…
Stress Testing Solutions Market Exploring Opportunities in Macroprudential Stres …
Increase in demand for mobile applications with advanced features is expected to drive the stress testing solutions market considerably in next few years. In addition, factors such as rise in adoption of mobile devices, need to ensure systems can handle extreme workloads, and adoption of test automation services are expected to majorly drive growth of the market. However, data management & data quality issues and uncertainties about easy availability of…
Stress Management 2023
Globally, the COVID-19 pandemic affected not only the financial status but also the mental health of the individuals drastically which increased the stress management market to USD 18,700.9 million and expected to increase at a CAGR of 3.8% during the forecast period. Globally, 10% of the children encounter any least one of the mental disorders. The preliminary treatment could be discussing the issue with the cherished circle, whereas professional…
Agrow Plant Stress Products
ReportsWorldwide has announced the addition of a new report title Agrow Plant Stress Products 2016 to its growing collection of premium market research reports.
Abiotic stresses such as heat, cold and drought prevent crops from reaching their full potential productivity. Plant stress products are a new category, increasing the tolerance of crop plants to these and other adverse environments. They span conventional pesticides with ‘crop enhancement’ or ‘plant health’ promoting properties,…
National Stress Awareness Day
National Stress Awareness Day is on Wednesday 5th November 2014. Relaxa is offering employee stress & wellbeing health promotion packages starting at £255 on or around this date - incorporating a range of stress & wellbeing activities for your staff.
There are 9 cost-effective stress and wellbeing promotion packages available below:
1) Stress Health Promotion Package 1 - £255.00+vat
2) Stress Health Promotion Package 2 - £399.00+vat
3) Stress Health Promotion Package 3…
